Helicobacter pylori and hypergastrinaemia during proton pump inhibitor therapy

Scand J Gastroenterol. 1992;27(2):93-8. doi: 10.3109/00365529209165424.


The rise in serum gastrin and pepsinogen I after 5 days' treatment with the proton pump inhibitor pantoprazole (40 mg/day) was examined in eight duodenal ulcer patients with Helicobacter pylori infection and compared with eight in whom it had been eradicated. Before treatment, the post-prandial serum gastrin concentrations were higher in the H. pylori-positive than -eradicated patients (p less than 0.05). The median rise in pre-prandial serum gastrin concentrations on treatment was similar in the H. pylori-positive (41%) and -eradicated patients (45%). The rise in post-prandial serum gastrin was also similar in the H. pylori-positive (81%) and -eradicated patients (69%), resulting in significantly higher gastrin concentrations during treatment in the former. The median rise in serum pepsinogen I on treatment was greater in the H. pylori-positive (114%) than in the -eradicated patients (8%), resulting in significantly higher concentrations during treatment in the former. These observations indicate that eradication of H. pylori may be a means of moderating the hypergastrinaemia caused by acid-inhibitory therapy. They also indicate that H. pylori-related hypergastrinaemia is not due to an increase of the antral surface pH by the bacterium's urease activity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Adenosine Triphosphatases / antagonists & inhibitors*
  • Benzimidazoles / pharmacology*
  • Benzimidazoles / therapeutic use
  • Duodenal Ulcer / blood
  • Duodenal Ulcer / drug therapy
  • Duodenal Ulcer / metabolism
  • Gastric Acidity Determination
  • Gastrins / blood*
  • Gastrins / drug effects
  • Helicobacter Infections / blood*
  • Helicobacter Infections / metabolism
  • Helicobacter pylori*
  • Humans
  • Male
  • Omeprazole / analogs & derivatives
  • Pantoprazole
  • Pepsinogen A*
  • Pepsinogens / blood*
  • Pepsinogens / drug effects
  • Peptide Fragments / blood*
  • Peptide Fragments / drug effects
  • Sulfoxides / pharmacology*
  • Sulfoxides / therapeutic use


  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Benzimidazoles
  • Gastrins
  • Pepsinogens
  • Peptide Fragments
  • Sulfoxides
  • pepsinogen (1-12)
  • Pepsinogen A
  • Pantoprazole
  • Adenosine Triphosphatases
  • Omeprazole